Extended treatment of abrocitinib: evaluation of efficacy and safety in chronic actinic dermatitis | Synapse
March 3, 2026Open Access
Extended treatment of abrocitinib: evaluation of efficacy and safety in chronic actinic dermatitis
Key Points
Abrocitinib shows effectiveness in managing chronic actinic dermatitis (CAD), providing a potential new treatment option.
The key factors influencing treatment success include interleukin-13 (IL-13) and CCL-4 expression levels in the patients.
Evaluation was based on comprehensive data analysis to assess both efficacy and safety outcomes.
The findings highlight the need for further exploration of abrocitinib as a treatment for chronic actinic dermatitis.
Abstract
The analysis of our data demonstrates that abrocitinib may be an effective therapeutic option in the management of CAD. IL-13 and CCL-4 might be the core effective factors after the therapy.